Piramal Pharma Ltd (PPLPHARMA) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Neuland Labs.

Emcure Pharma

J B Chemicals &

Astrazeneca Phar

Ipca Labs

ERIS Lifescience

Pfizer

Ajanta Pharma

Gland Pharma

Wockhardt

Piramal Pharma

Why is Piramal Pharma Ltd ?

Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.83 times

Poor long term growth as Net Sales has grown by an annual rate of 9.15% over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of 3.83 times
The company has been able to generate a Return on Equity (avg) of 0.32% signifying low profitability per unit of shareholders funds

Negative results in Sep 25

PBT LESS OI(Q) At Rs -111.78 cr has Fallen at -340.0% (vs previous 4Q average)
PAT(Q) At Rs -99.22 cr has Fallen at -613.2% (vs previous 4Q average)
NET SALES(Q) At Rs 2,043.72 cr has Fallen at -10.5% (vs previous 4Q average)

Below par performance in long term as well as near term

Along with generating -34.60% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Piramal Pharma for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Piramal Pharma

-34.33%

-0.95

36.61%

Sensex

4.73%

0.41

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.15%

EBIT Growth (5y)

23.29%

EBIT to Interest (avg)

0.80

Debt to EBITDA (avg)

5.08

Net Debt to Equity (avg)

0.51

Sales to Capital Employed (avg)

0.64

Tax Ratio

100.00%

Dividend Payout Ratio

81.66%

Pledged Shares

Institutional Holding

45.17%

ROCE (avg)

2.65%

ROE (avg)

0.32%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.97

EV to EBIT

86.63

EV to EBITDA

24.14

EV to Capital Employed

2.31

EV to Sales

3.15

PEG Ratio

Dividend Yield

0.06%

ROCE (Latest)

2.66%

ROE (Latest)

-0.55%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

OPERATING CF(Y)

Highest at Rs 548.77 Cr

-10What is not working for the Company

PBT LESS OI(Q)

At Rs -111.78 cr has Fallen at -340.0% (vs previous 4Q average

PAT(Q)

At Rs -99.22 cr has Fallen at -613.2% (vs previous 4Q average

NET SALES(Q)

At Rs 2,043.72 cr has Fallen at -10.5% (vs previous 4Q average

EPS(Q)

Lowest at Rs -0.75

Loading Valuation Snapshot...

Here's what is working for Piramal Pharma

Operating Cash Flow - Annually

Highest at Rs 548.77 Cr and Grown

each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Here's what is not working for Piramal Pharma

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs -111.78 cr has Fallen at -340.0% (vs previous 4Q average)

over average PBT of the previous four quarters of Rs 46.57 Cr

MOJO Watch

Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs -99.22 cr has Fallen at -613.2% (vs previous 4Q average)

over average PAT of the previous four quarters of Rs 19.33 Cr

MOJO Watch

Near term PAT trend is very negative

PAT (Rs Cr)

Net Sales - Quarterly

At Rs 2,043.72 cr has Fallen at -10.5% (vs previous 4Q average)

over average Net Sales of the previous four quarters of Rs 2,283.44 Cr

MOJO Watch

Near term sales trend is very negative

Net Sales (Rs Cr)

Earnings per Share (EPS) - Quarterly

Lowest at Rs -0.75

in the last five quarters

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (Rs)

Non Operating Income - Quarterly

Highest at Rs 65.60 cr

in the last five quarters

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating Income